SEC Form 4 · accession 0000950138-18-000043
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Coleman N Lannum III
Officer — Sr. VP Investor Strategy & IRO
Period of report
Jan 3, 2018
Accepted (ET)
Jan 5, 2018 · 7:28 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Jan 3, 2018 | F | 412 | $23.51 | D | 32,843 | D | |
| Ordinary Shares | Jan 4, 2018 | F | 518 | $23.40 | D | 32,325 | D | |
| Ordinary Shares | holding | — | — | — | 3,000 | I | By Wife | |
| Ordinary Shares | holding | — | — | — | 75 | I | By son (M) | |
| Ordinary Shares | holding | — | — | — | 45 | I | By son (R) | |
| Ordinary Shares | holding | — | — | — | 45 | I | By son (S) | |
| Ordinary Shares | holding | — | — | — | 20 | I | By mother |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes 250 shares acquired on June 30, 2017 under the Mallinckrodt employee stock purchase plan.